focus -WSS

focus

author：entertainment 2025-09-27 19:01:56 - browse：13

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： ReNAgade cuts staff seven months after raising $300 million

WSS

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

30 years of 'Listening to Prozac'

Diagnostic tests are hitting their mathematical limits

Indian pharmaceutical industry in denial over drug

Fetal surgery at risk from Dobbs and new abortion restrictions

Stanford president's case begs question: Who takes blame?

leisure time

focus

focus

How to save PrEP access — and even expand it

Study identifies new proteins linked to dementia risk 25 years later

Continuity nursing helped my family in our darkest PICU moments

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Drug repurposing or repositioning? The language matters

Study identifies new proteins linked to dementia risk 25 years later

Activists slam private health insurers over coverage restrictions

ReNAgade cuts staff seven months after raising $300 million

ChatGPT in medicine: STAT answers readers' burning questions

Tocagen's brain cancer gene therapy trial continues. Investors worry

explore

Takeda, Janssen join wearable maker to measure scratching

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

FDA investigates CAR

Pediatric cancer treatments threatened by a new FDA policy

30 years of 'Listening to Prozac'

focus

entertainment

hotspot

Wikipedia